PTC Therapeutics Inc APHENITY Topline Results Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Congratulations on these really great data that you reported this morning. I just had 2 questions. The first one is, can you remind us what these blood Phe levels and coming within the guideline targets really means for patients from the perspective of symptomology of this indication and other factors related to PKU.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Okay. And then second question, I know you've done a lot of work on understanding the mechanistic differences between Kuvan, and you have the head-to-head study. But with this readout, you noted the 27 patients and the significant drop that we saw after treatment on for PTC. So can you talk about the validation from these data with the mechanistic differences that you see between the 2 therapies, especially now that you have these additional 27 patients.

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Congrats on the really great data. I think we've covered most of what we have, but maybe just on what was the level of Phe reduction in part 2 for the patients who had a 15% to 30% Phe reduction in Part 1, so if I missed that. And then just thinking about sort of the commercial side of the story, what -- how should we be thinking about launch prep and sales force build-out? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 17, 2023 / 12:00PM, PTCT.OQ - PTC Therapeutics Inc APHENITY Topline Results Call